PEGylated silk nanoparticles for anticancer drug delivery

Thidarat Wongpinyochit, Petra Uhlmann, Andrew J. Urquhart, F. Philipp Seib

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Silk has a robust clinical track record and is emerging as a promising biopolymer for drug delivery, including its use as nanomedicine. However, silk-based nanomedicines still require further refinements for full exploitation of their potential; the application of "stealth" design principals is especially necessary to support their evolution. The aim of this study was to develop and examine the potential of PEGylated silk nanoparticles as an anticancer drug delivery system. We first generated B. mori derived silk nanoparticles by driving β-sheet assembly (size 104 ± 1.7 nm, zeta potential -56 ± 5.6 mV) using nanoprecipitation. We then surface grafted polyethylene glycol (PEG) to the fabricated silk nanoparticles and verified the aqueous stability and morphology of the resulting PEGylated silk nanoparticles. We assessed the drug loading and release behavior of these nanoparticles using clinically established and emerging anticancer drugs. Overall, PEGylated silk nanoparticles showed high encapsulation efficiency (>93%) and a pH-dependent release over 14 days. Finally, we demonstrated significant cytotoxicity of drug loaded silk nanoparticles applied as single and combination nanomedicines to human breast cancer cells. In conclusion, these results, taken together with prior silk nanoparticle data, support a viable future for silk-based nanomedicines.
LanguageEnglish
Pages3712-3722
Number of pages11
JournalBiomacromolecules
Volume16
Issue number11
DOIs
Publication statusPublished - 9 Nov 2015

Fingerprint

Silk
Drug delivery
Nanoparticles
Nanomedicine
Medical nanotechnology
Pharmaceutical Preparations
Morus
Biopolymers
Zeta potential
Drug Delivery Systems
Cytotoxicity
Encapsulation
Polyethylene glycols
Cells
Breast Neoplasms

Keywords

  • drug delivery
  • silk nanoparticles
  • anticancer drugs

Cite this

Wongpinyochit, Thidarat ; Uhlmann, Petra ; Urquhart, Andrew J. ; Seib, F. Philipp. / PEGylated silk nanoparticles for anticancer drug delivery. In: Biomacromolecules. 2015 ; Vol. 16, No. 11. pp. 3712-3722.
@article{6387cf96b60f48e8b604120a251c7943,
title = "PEGylated silk nanoparticles for anticancer drug delivery",
abstract = "Silk has a robust clinical track record and is emerging as a promising biopolymer for drug delivery, including its use as nanomedicine. However, silk-based nanomedicines still require further refinements for full exploitation of their potential; the application of {"}stealth{"} design principals is especially necessary to support their evolution. The aim of this study was to develop and examine the potential of PEGylated silk nanoparticles as an anticancer drug delivery system. We first generated B. mori derived silk nanoparticles by driving β-sheet assembly (size 104 ± 1.7 nm, zeta potential -56 ± 5.6 mV) using nanoprecipitation. We then surface grafted polyethylene glycol (PEG) to the fabricated silk nanoparticles and verified the aqueous stability and morphology of the resulting PEGylated silk nanoparticles. We assessed the drug loading and release behavior of these nanoparticles using clinically established and emerging anticancer drugs. Overall, PEGylated silk nanoparticles showed high encapsulation efficiency (>93{\%}) and a pH-dependent release over 14 days. Finally, we demonstrated significant cytotoxicity of drug loaded silk nanoparticles applied as single and combination nanomedicines to human breast cancer cells. In conclusion, these results, taken together with prior silk nanoparticle data, support a viable future for silk-based nanomedicines.",
keywords = "drug delivery, silk nanoparticles, anticancer drugs",
author = "Thidarat Wongpinyochit and Petra Uhlmann and Urquhart, {Andrew J.} and Seib, {F. Philipp}",
year = "2015",
month = "11",
day = "9",
doi = "10.1021/acs.biomac.5b01003",
language = "English",
volume = "16",
pages = "3712--3722",
journal = "Biomacromolecules",
issn = "1525-7797",
publisher = "American Chemical Society",
number = "11",

}

PEGylated silk nanoparticles for anticancer drug delivery. / Wongpinyochit, Thidarat; Uhlmann, Petra; Urquhart, Andrew J.; Seib, F. Philipp.

In: Biomacromolecules, Vol. 16, No. 11, 09.11.2015, p. 3712-3722.

Research output: Contribution to journalArticle

TY - JOUR

T1 - PEGylated silk nanoparticles for anticancer drug delivery

AU - Wongpinyochit, Thidarat

AU - Uhlmann, Petra

AU - Urquhart, Andrew J.

AU - Seib, F. Philipp

PY - 2015/11/9

Y1 - 2015/11/9

N2 - Silk has a robust clinical track record and is emerging as a promising biopolymer for drug delivery, including its use as nanomedicine. However, silk-based nanomedicines still require further refinements for full exploitation of their potential; the application of "stealth" design principals is especially necessary to support their evolution. The aim of this study was to develop and examine the potential of PEGylated silk nanoparticles as an anticancer drug delivery system. We first generated B. mori derived silk nanoparticles by driving β-sheet assembly (size 104 ± 1.7 nm, zeta potential -56 ± 5.6 mV) using nanoprecipitation. We then surface grafted polyethylene glycol (PEG) to the fabricated silk nanoparticles and verified the aqueous stability and morphology of the resulting PEGylated silk nanoparticles. We assessed the drug loading and release behavior of these nanoparticles using clinically established and emerging anticancer drugs. Overall, PEGylated silk nanoparticles showed high encapsulation efficiency (>93%) and a pH-dependent release over 14 days. Finally, we demonstrated significant cytotoxicity of drug loaded silk nanoparticles applied as single and combination nanomedicines to human breast cancer cells. In conclusion, these results, taken together with prior silk nanoparticle data, support a viable future for silk-based nanomedicines.

AB - Silk has a robust clinical track record and is emerging as a promising biopolymer for drug delivery, including its use as nanomedicine. However, silk-based nanomedicines still require further refinements for full exploitation of their potential; the application of "stealth" design principals is especially necessary to support their evolution. The aim of this study was to develop and examine the potential of PEGylated silk nanoparticles as an anticancer drug delivery system. We first generated B. mori derived silk nanoparticles by driving β-sheet assembly (size 104 ± 1.7 nm, zeta potential -56 ± 5.6 mV) using nanoprecipitation. We then surface grafted polyethylene glycol (PEG) to the fabricated silk nanoparticles and verified the aqueous stability and morphology of the resulting PEGylated silk nanoparticles. We assessed the drug loading and release behavior of these nanoparticles using clinically established and emerging anticancer drugs. Overall, PEGylated silk nanoparticles showed high encapsulation efficiency (>93%) and a pH-dependent release over 14 days. Finally, we demonstrated significant cytotoxicity of drug loaded silk nanoparticles applied as single and combination nanomedicines to human breast cancer cells. In conclusion, these results, taken together with prior silk nanoparticle data, support a viable future for silk-based nanomedicines.

KW - drug delivery

KW - silk nanoparticles

KW - anticancer drugs

UR - http://pubs.acs.org/doi/abs/10.1021/acs.biomac.5b01003

U2 - 10.1021/acs.biomac.5b01003

DO - 10.1021/acs.biomac.5b01003

M3 - Article

VL - 16

SP - 3712

EP - 3722

JO - Biomacromolecules

T2 - Biomacromolecules

JF - Biomacromolecules

SN - 1525-7797

IS - 11

ER -